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Cdc53 Targets Phosphorylated G1 Cyclins for
Degradation by the Ubiquitin Proteolytic Pathway
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transitions, Cdc28 is activated by binding to distinctTimothy F. Nason,4, 7 Neal Mathias,5 Ryuji Kobayashi,6
groups of cyclins. The G1 cyclins Cln1 and Cln2 areCurt Wittenberg,3 and Mike Tyers1, 2
maximally expressed at Start, in a manner that depends1Programme in Molecular Biology and Cancer
on a third G1 cyclin, Cln3, which itself is only modestlySamuel Lunenfeld Research Institute
cell cycle regulated (Wittenberg et al., 1990; Tyers et al.,Mount Sinai Hospital
1993; Dirick et al., 1995; Stuart and Wittenberg, 1995).600 University Avenue
Passage through Start is sensitive to Cln abundance,Toronto, Canada M5G 1X5
and cells that lack Cln function arrest at Start (reviewed2Department of Molecular and Medical Genetics
by Cross, 1995). All cell cycle events subsequent to StartUniversity of Toronto
require B-type (Clb) cyclin function (Schwob et al., 1994).Toronto, Canada M5S 1A8
Clb5 and Clb6 are also expressed at Start, and activate3Departments of Molecular and Cell Biology
Cdc28 for the initiation of DNA replication (Schwob andThe Scripps Research Institute
Nasmyth, 1993). The remaining mitotic cyclins, Clb1–10550 North Torrey Pines Road
Clb4, are expressed later in the cell cycle and are re-La Jolla, California 92037
quired for the onset of mitosis and possibly also for4C.H. Best Institute
the completion of DNA replication (Fitch et al., 1992;University of Toronto
Richardson et al., 1992).Toronto, Canada M5G 1L6
Cyclin abundance isoften rate limiting for Cdk activity,5Department of Biochemistry and Molecular Biology
and by controlling rates of cyclin synthesis and degrada-Walther Oncology Center
tion the cell is able to regulate cell cycle transitionsIndiana University School of Medicine
(reviewed by Murray, 1995). The important role of selec-Indianapolis, Indiana 46202
tive protein degradation in cell division was presaged6Cold Spring Harbor Laboratory
by the discovery of mitotic cyclins on the basis of their1 Bungtown Road
catastrophic destruction at mitosis (Evans et al., 1983).Cold Spring Harbor, New York 11724
A short conserved sequence motif called thedestruction
box targets mitotic cyclins to the ubiquitin proteolytic
pathway (Glotzer et al., 1991). In this pathway, ubiquitinSummary
is first activated in an ATP-dependent manner by a thio-
ester linkage to a ubiquitin-activating enzyme (E1) and
In budding yeast, cell division is initiated in late G1
then transferred to a ubiquitin-conjugating enzyme (E2),
phaseonce the Cdc28 cyclin-dependent kinase is acti-
also via a thioester intermediate. Ubiquitin is transferred
vated by the G1 cyclins Cln1, Cln2, and Cln3. The ex-
to target proteins by the E2, often in combination with
treme instability of the Cln proteins couples environ- a ubiquitin–protein ligase (E3). The ubiquitin–target pro-
mental signals, which regulate Cln synthesis, to cell tein conjugate is formed through an isopeptide bond
division. We isolated Cdc53 as a Cln2-associated pro- between the carboxy-terminal glycine of ubiquitin and
tein andshow thatCdc53 is required for Cln2 instability a lysine residue on the target protein. Repeated ubiquiti-
and ubiquitination in vivo. The Cln2–Cdc53 interaction, nation reactions culminate in attachment of a multi-
Cln2 ubiquitination, and Cln2 instability all depend on ubiquitin chain that marks the target protein for rapid
phosphorylation of Cln2. Cdc53 also binds the E2 ubi- degradation by the 26S proteasome (reviewed by Hoch-
quitin-conjugating enzyme, Cdc34. These findings strasser, 1995). The E3 ubiquitin–protein ligase activity
suggest that Cdc53 is a component of a ubiquitin– that ubiquitinates B-type cyclins resides in a large multi-
protein ligase complex that targets phosphorylated G1 protein complex known as the anaphase-promoting
cyclins for degradation by the ubiquitin–proteasome complex (APC) or cyclosome (Hershko et al., 1994; King
pathway. et al., 1995; Sudakin et al., 1995). Mutations in APC
components arrest yeast cells at the metaphase to ana-
Introduction phase transition (Irniger et al., 1995). The APC is regu-
lated by phosphorylation (Sudakin et al., 1995) and is
Eukaryotic cell division is controlled by members of the active from anaphase until Start, corresponding to the
cyclin-dependent kinase (Cdk) family. Cdk activity is window of mitotic cyclin instability in yeast (Amon et al.,
subject to regulation by phosphorylation, association 1994).
with positive regulatory subunits known as cyclins, and Selective proteolysis is central to the events that con-
binding to Cdk inhibitor proteins (reviewed by Pines, stitute the Start decision in late G1 phase. Elaboration
1995). The budding yeast Saccharomyces cerevisiae of Clb5/Clb6–Cdc28 activity and the initiation of DNA
has a single essential Cdk (called Cdc28 or Cdk1) that replication is contingent on the elimination of a Clb–
catalyzes entry into a new division cycle in late G1 phase Cdc28 inhibitor called p40SIC1 (Mendenhall, 1993; Nu-
groho and Mendenhall, 1994), which holds Clb5/Clb6–
Cdc28 in check until cells have passed Start.7 Present address: Eli Lilly Canada Inc., 3650 Danforth Avenue, Scar-
borough, Ontario, Canada M1N 2E8. Phosphorylation of p40SIC1 by the Cln–Cdc28 kinases at
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Start may target p40SIC1 for ubiquitination by the Cdc34 To allow specific detection of Cln2-associated proteins,
ubiquitin-conjugating enzyme (Schwob et al., 1994; we used a CLN2 allele that was tagged with a triple
Schneider et al., 1996; Tyers, 1996). Two other proteins, influenza hemagglutinin (HA) epitope recognized by the
Cdc4 and Cdc53, are also implicated in the degradation 12CA5 monoclonal antibody (Tyers et al., 1993). To max-
of p40SIC1 because, like cdc34 mutants, cdc4 and cdc53 imize the likelihood of identifying G1-specific proteins,
mutants arrest with unreplicated DNA and multiple elon- we overexpressed CLN2HA from the ADH1 promoter in
gated buds (Yochem and Byers, 1987; Goebl et al., 1988; a cdc34-2 strain arrested at the nonpermissive tempera-
Mathias et al., submitted). Recently, a protein called ture in late G1 phase when Cln2 abundance and Cln2–
Skp1 has been shown to interact directly with Cdc4 and Cdc28 kinase activity are maximal (Wittenberg et al.,
to be necessary for p40SIC1 proteolysis (Bai et al., 1996). 1990; Tyers et al., 1993). Proteins retained on 12CA5
In addition to catalyzing cell cycle transitions, protein antibody columns from the CLN2HA lysate, but not from
degradation is critical for the proper integration of Cdk an untagged control lysate, were identified by SDS–
activity with environmental signals. Usually this integra- polyacrylamide gel electrophoresis (SDS–PAGE) (Figure
tion occurs in G1 phase, whether it be nutrient sensing 1A). The validity of this approach was established by
in yeast or growth factor signaling in mammalian cells the specific retention of two proteins known to interact
(reviewed bySherr, 1994). Cln1, Cln2, and Cln3 are highly with Cln2. Cdc28, the cognate Cdk for Cln2 (Wittenberg
unstable proteins, a characteristic that is essential for et al., 1990), was identified as a predominant 34 kDa
the coordination of Start with nutrient availability and species among the retained proteins by immunoblotting
the presence of mating pheromones. In part, these envi- with anti-Cdc28 antibody (data not shown). Cks1, a small
ronmental cues repress CLN transcription, and this protein known to bind Cdc28 complexes (Hadwiger et
leads to G1 arrest because Cln proteins are rapidly de- al., 1989a), was identified by direct microsequencing of
pleted. For instance, CLN1 is repressed by glucose- a 21 kDa polypeptide in Cln2HA eluates (data not shown).
mediated activation of the Ras/cAMP pathway, and this A prominent species of 94 kDa was also specifically
accounts for a cell cycle delay at Start (Baroni et al., retained from a Cln2HA lysate, but not from an untagged
1994; Tokiwa et al., 1994). Conversely, mutations that control lysate (Figure 1A). Microsequencing of peptides
stabilize Cln proteins, such as CLN2-1, CLN24T3S, and derived from this band yielded 14 internal peptide se-
CLN3-1, confer resistance to mating pheromone and quences. A search of a private database maintained
nutrient arrest (Cross, 1988; Nash et al., 1988; Hadwiger by M. Goebl (Indiana University College of Medicine)
et al., 1989b; Lanker et al., 1996). The determinants for
revealed that 11 of the peptide sequences matched the
Cln instability were first defined by the CLN2-1 and
amino acid sequence deduced from the CDC53 gene
CLN3-1 mutations, which encode truncated proteins
(Figure 1B),which had been cloned previously (M. Goebl,
that lack carboxy-terminal PEST sequences. Such se-
personal communication; Mathias et al., submitted).
quences often occur in unstable proteins (Rogers et al.,
The complex containing Cdc53 and Cln2 was not re-
1986) and are also present in human G1 cyclins (Lew et
stricted to cells arrested by the cdc34-2 mutation, sinceal., 1991). Recently, phosphorylation of specific Cdc28
Cdc53 was identified in 12CA5 column eluates fromconsensus sites in the carboxyl terminus of Cln2 and
asynchronous wild-type cultures expressing pADH1-Cln3 has been implicated in Cln instability (Yaglom et
CLN2HA (Figure 1C). In this experiment, small-scale ana-al., 1995; Lanker et al., 1996). In particular, a mutant
lytical columns were used, and Cdc53 was detectedversion of Cln2 that lacks seven Cdc28 consensus phos-
by immunoblotting with polyclonal antibodies directedphorylationsites is hyperstable and causes deregulation
against Cdc53. The Cln2–Cdc53 complex was disruptedof Start (Lanker et al., 1996). Several proteins have been
by elution with 1 M NaCl, suggesting that it dependsimplicated in Cln instability, including Cdc34 (Deshaies
upon charged interactions (Sopta et al., 1985). In con-et al., 1995), Skp1 (Bai et al., 1996), and a leucine-rich
trast, the interaction between Cln2 and Cdc28 was sta-repeat protein, Grr1 (Barral et al., 1995). It has been
ble to 1 M NaCl, but was disrupted by 1% SDS (Fig-proposed that Cln degradation proceeds via the ubiqui-
ure 1C).tin pathway, since Cln2 is ubiquitinated in vitro in cell
Aside from p34CDC28 and p21CKS1, p94CDC53 was the mostextracts in a Cdc28- and Cdc34-dependent manner (De-
prominent species detected in Cln2HA eluates, sug-shaies et al., 1995).
gesting that the Cln2–Cdc53 interaction is direct. How-We have identified Cdc53 as a Cln2-associated pro-
ever, we cannot yet exclude the possibility that Cln2tein and show that Cln2 instability and ubiquitination in
interacts with Cdc53 via another protein that is eithervivo require Cdc53 function. Formation of the Cln2–
visualized poorly by direct protein staining or is presentCdc53 complex and ubiquitination of Cln2 in vivo both
in substoichiometric amounts but capable of bridgingdepend on phosphorylation of the Cln2 carboxy-termi-
several Cln2–Cdc53 interactions.nal domain. Since we observe that Cdc53 physically
interacts with Cdc34, we suggest that Cdc53 forms part
of a ubiquitin–protein ligase complex that targets phos-
Cdc53 Specifically Complexes with G1 Cyclinsphorylated Clns for rapid degradation by the ubiquitin
The Cln2–Cdc53 complex detected by immunoaffinitypathway.
chromatography was confirmed by specific coimmuno-
precipitation of the two proteins from yeast lysates.Results
Cdc53 was detected in 12CA5 immunoprecipitates of
Cln2HA by immunoblotting with an anti-Cdc53 antibodyIdentification of Cdc53 as a
(Figure 2A, lanes 4 and 7). Cdc53 was absent from con-Cln2-Associated Protein
trol immunoprecipitates that were either prepared fromWe used immunoaffinity column chromatography to
identify proteins that interact with Cln2 in yeast lysates. strains expressing untagged Cln2, carried out in the
Cdc53 Mediates G1 Cyclin Degradation
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Figure 1. Identification of Cdc53 as a Cln2-
Associated Protein
(A) A 94 kDa protein (p94) is specifically re-
tained from Cln2HA lysates. Lysate from a
cdc34-2 strain with (GT101-14c; lane 3) or
without (RN200-6d; lane 2) a <pADH1-
CLN2HA> plasmid (pCB1317) was purified on
a 12CA5 antibody column. Retained proteins
were resolved by SDS–PAGE and visualized
by silver stain.
(B) Identity between peptides derived from
p94 and the deduced Cdc53 amino acid se-
quence.
(C) Cdc53 forms a complex with Cln2HA in
wild-type asynchronous cells. Lysates from
asynchronous cultures of a wild-type strain
(K699) with (CLN2HA panels) or without (un-
tagged panels) a <pADH1-CLN2HA> plasmid
(pCB1317) werechromatographed on an ana-
lytical scale 12CA5 antibody column. The col-
umn was washed with 0.1 M NaCl in affinity
column buffer (ACB; wash), and retained pro-
teins were eluted with 1 M NaCl in ACB(NaCl),
1% SDS in ACB (SDS), and 100 mM triethyla-
mine (TEA). Eluted proteins were immu-
noblotted with 12CA5 antibody, anti-Cdc28
antibody, and anti-Cdc53 antibody.
presence of excess competing HA peptide, or carried retards proliferation of a cdc34 strain (Deshaies et al.,
1995). We found that overexpression of CLN2 or CLN3out in the absence of 12CA5 antibody (Figure 2A, lanes
1–3, 5, and 6). As expected, immunoprecipitation of in a cdc53-1 strain impaired colony formation at 308C
(Figure 2C). In contrast, CLN1 overexpression failed toCdc53MYC also specifically coprecipitated Cln2HA (see be-
low). Comparison to total Cdc53 in cell lysates indicated enhance the cdc53-1phenotype at 308C, consistent with
the weaker interaction between Cln1 and Cdc53. Sur-that approximately 1% of total cellular Cdc53 coimmu-
noprecipitated with Cln2. prisingly, whenCLN3-1 was overexpressed, the cdc53-1
strain was viable at 308C, despite the fact that Cln3-1To determine whether other yeast cyclin complexes
also contained Cdc53, we coexpressed HA-tagged ver- hyperactivates Start and has 10- to 100-fold more asso-
ciated kinase activity in vitro than Cln3 (Tyers et al.,sions of each of the three G1 cyclins, the S phase cyclin
Clb5, and the G2/M phase cyclin Clb2 with a functional 1992). This suggested that the carboxy-terminal region
of Cln3, and presumably also Cln2, specifically inter-Cdc53protein tagged with six tandemly repeatedcopies
of the MYC epitope (referred toas Cdc53MYC). In coimmu- fered with Cdc53 function (see below). The ability of a
cdc53-1 strain to form colonies at 308C was not affectednoprecipitation experiments, Cdc53MYC interacted spe-
cifically with all three G1 cyclins, but not with either by overexpression of either CLB5 or CLB2 (data not
shown).B-type cyclin (Figure 2B). As a control, Cdc28 was de-
tected in each of the cyclin immunoprecipitates (Fig-
ure 2B). Stable Cln Mutants Do Not Form a Complex
with Cdc53To evaluate the possible significance of Cln–Cdc53
complexes in vivo, we tested for genetic interactions The similar cell cycle arrest phenotype of cdc34 and
cdc53 mutants (Mathias et al., submitted) suggestedbetweenCLN overexpressionand the cdc53-1 mutation.
It has previously been shown that CLN2 overexpression that Cdc53 may be involved in Cln2 degradation. To
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mutants, Cln2-1 and Cln3-1. In coimmunoprecipitation
experiments, we found that Cdc53 interacted with
Cln2-1 and Cln3-1 much less effectively than with their
wild-type counterparts (Figure 3A, lanes 3 and 5). The
inability of Cln3-1 and Cdc53 to form a complex provides
a possible explanation for the absence of a genetic inter-
action between CLN3-1 overexpression and the cdc53-1
mutation.
To examine further the role of the carboxy-terminal
domain of Cln2 in the Cln2–Cdc53 interaction, we evalu-
ated the capacity of Cdc53 to interact with Cln24T3S, a
mutant in which all seven Cdc28 consensus phosphory-
lation sites in the carboxy-terminal region of Cln2 are
converted to alanine. Although Cln24T3S still binds and
activates Cdc28, it is underphosphorylated in vivo and
is approximately 8-fold more stable than wild-type Cln2
and results in a constellation of phenotypes characteris-
tic of G1 cyclin hyperactivation (Lanker et al., 1996).
We found that coimmunoprecipitation of Cdc53MYC with
Cln24T3S was dramatically reduced relative to wild-type
Cln2 (Figure 3A, lane 7).
The failure of Cdc53 to interact with Cln24T3S suggests
that phosphorylation of Cln2 is important for the interac-
tion. We extended this correlation by determining that
only hyperphosphorylated Cln2 was present in Cdc53
coimmunoprecipitates (Figure 3B, lane 4). Conversely,
hypophosphorylated Cln2 accumulated in cells arrested
by the cdc28-4 mutation failed to complex with Cdc53
(Figure 3B, lane 7). We have also detected a specific
interaction between Cdc53 from yeast extracts and hyp-
erphosphorylated forms of Cln2 immobilized on a filter
after resolution by SDS–PAGE (data not shown).
To test directly the role of phosphorylation in Cln2–
Cdc53 complex formation, we established that Cdc53
Figure 2. Cdc53 Specifically Forms Complexes with G1 Cyclins from yeast lysates could interact with previously immu-
(A) Coimmunoprecipitation of Cdc53 with Cln2HA. Lysates from an noprecipitated Cln2 in a rebinding assay (Figure 3C, lane
untaggedcdc34-2 strain (RN200-6d; lane 1), a CLN2HA cdc34-2 strain 4). Treatment of Cln2 immunoprecipitates with alkaline
(GT101-14c; lanes 2–4), or a cdc34-2 strain containing a <pADH1-
phosphatase collapsed the Cln2 phosphorylation smearCLN2HA> plasmid (GT101-14c plus pCB1317; lanes 5–7) that had
down to a single hypophosphorylated form and abro-been arrested at 378C for 4 hr were immunoprecipitated with 12CA5
gated Cdc53 binding (Figure 3C, lane 8). In contrast, theantibody (lanes 1, 3, 4, 6, and 7) or no antibody (lanes 2 and 5) and
immunoblotted with 12CA5 antibody, anti-Cdc28 antibody,and anti- Cln2–Cdc28 interaction was not perturbed by phospha-
Cdc53 antibody. As a control, binding of Cln2HA to the 12CA5 anti- tase treatment. Cln2 immunoprecipitates treated with
body was prevented with excess free HA peptide (lanes 3 and 6). phosphatase in the presence of inhibitors remained
(B) Interaction of Cdc53 with various cyclins. Lysates from wild-type
competent for Cdc53 binding, eliminating the possibilitycells containing a <CDC53C-MYC6> plasmid (pMT843) and either an
of nonspecific disruption of the Cln2–Cdc53 complexempty vector plasmid (pRS316; lane 1) or plasmids expressing vari-
by the phosphatase (Figure 3C, lane 6). Finally, Cln24T3Sous HA-tagged cyclins from the GAL1 promoter were immunopre-
cipitated with 12CA5 antibody and immunoblotted with 12CA5 anti- also did not bind Cdc53 in this assay (data not shown).
body,anti-Cdc28 antibody,and 9E10 antibody. Plasmids expressing These results confirm that loss of Cdc53 binding to
HA-tagged cyclins were as follows: <pGAL1-CLN1HA> (pMT485; lane Cln24T3S arises from the inability of the mutant protein to
2); <pGAL1-CLN2HA> (pMT634; lane 3); <pGAL1-CLN3HA> (pMT41;
be phosphorylated and not from mutation of the Ser/lane 4); <pGAL1-CLB5HA> (pWS12933; lane 5); and <pGAL1-CLB2HA>
Thr residues per se. Thus, phosphorylation of specific(pWS935; lane 6). Asterisk indicates position of the immunoglobulin
carboxy-terminal residues in Cln2 is essential for theG (IgG) heavy chain, and plus indicates Clb degradation products.
(C) Overexpression of CLN2 and CLN3 inhibits proliferation of a Cln2–Cdc53 interaction, which suggests that Cdc53
cdc53-1 strain. Wild-type (K699) or cdc53-1 (MTY740) cells con- may specifically target phosphorylated Cln2 for rapid
taining no plasmid, an empty vector plasmid (pRS316), or plasmids degradation.
expressing CLN1 (pMT485), CLN2 (pMT634), CLN3 (pMT41), or
CLN3-1 (pMT215 for wild type; pMT42 for cdc53-1) from the GAL1
promoter were grown on galactose plates lacking uracil at 308C for
Cln2 Is Stabilized in cdc53 and cdc34 Mutants3 (wild type) or 5 (cdc53) days.
To establish a role for Cdc53 in Cln degradation directly,
we compared the half-life of Cln2 in a wild-type strain
with its half-life in a temperature-sensitive cdc53-1establish whether Cln–Cdc53 complex formation corre-
lated with Cln instability, we analyzed the interaction strain. For comparison, we also examined Cln2 half-life
in a cdc34-2 strain, which stabilizes Cln2 in some strainof Cdc53 with the stable carboxy-terminal truncation
Cdc53 Mediates G1 Cyclin Degradation
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Figure 4. Cln2 Instability Requires Cdc53 Function
(A) Cln2 is stabilized in cdc34 and cdc53 arrested cells. Wild-type
(MTY386), cdc53 (MTY784), and cdc34 (MTY777) strains were incu-
bated at 378C for 2 hr, after which pGAL1-CLN2HA was induced for
1.5 hr and then repressed by glucose treatment for the indicated
times. Samples were analyzed for Cln2HA and CLN2 mRNA; equal
loading for immunoblots and Northern blots was confirmed by de-
tection with anti-Cdc28 antibody and ACT1, respectively. For accu-
rate representation of Cln2HA decay rates, exposure times (indicated
under each panel) were adjusted to give equal Cln2HA signals at the
0 min timepoint to compensate for the elevated abundance of Cln2HA
in cdc34 and cdc53 strains.
(B) Cdc53-dependent Cln2 instability does not depend on the cdc53
arrest point. A similar experiment was carried out as in (A), except
that cultures were first prearrested with 200 mM hydroxyurea for
1.5 hr at 258C before shifting to 378C.
backgrounds (Deshaies et al., 1995; see also Salama et
al., 1994). Cln2 half-life was determined in promoterFigure 3. The Cln–Cdc53 Interaction Depends on Cln Phosphory-
shut-off experiments in which expression of a pGAL1-lation
CLN2HA construct was repressed by glucose and the rate(A) Stable mutant Cln proteins do not interact with Cdc53. Lysates
from the following strains, all carrying a <CDC53C-MYC6> plasmid of Cln2 degradation was determined by immunoblotting.
(pMT843), were immunoprecipitated with 12CA5 antibody: no tag Northern blot analysis of CLN2 mRNA confirmed that
(K699; lane 1); CLN2HA (MTY738; lane 2); CLN2-1HA (MTY251; lane expression of CLN2 from the GAL1 promoter was rapidly
3); pGAL1-CLN3HA (K699 plus pMT41; lane 4); pGAL1-CLN3-1HA
repressed in of each the strains (Figure 4A). As found(K699 plus pMT42; lane 5); pGAL1-CLN2HA (K699 plus pSL46; lane
previously, Cln2 was extremely unstable in wild-type6); pGAL1-CLN24T3S-HA (K699 plus pSL122; lane 7); no tag (K699 plus
pRS316; lane 8). Immunoprecipitates were immunoblotted with cells, becoming almost undetectable within 10 min fol-
12CA5 antibody, anti-Cdc28 antibody, and 9E10 antibody. Asterisk lowing repression of pGAL1-CLN2HA. In contrast, Cln2
indicates position of the IgG heavy chain.
protein levels decayed slowly in cdc53-1 and cdc34-2(B) Cdc53 complexes with hyperphosphorylated Cln2. A wild-type
strains, persisting for more than 90 min after promoterstrain (K699; lanes 2–4) or a cdc28-4 strain (K1989; lanes 5–7)
containing <pGAL1-CLN2HA> (pMT634) and, where indicated, repression (Figure 4A).
<CDC53C-MYC6> (pMT843) were incubated at 378C for 1.5 hr and in- It was unlikely that stabilization of Cln2 in cdc53 cells
duced with galactose for 0.5 hr. Lysates were immunoprecipitated was merely a consequence of the G1 arrest, since Cln2
with 9E10 antibody as indicated and immunoblotted with 9E10 anti-
instability has been previously demonstrated in variousbody and 12CA5 antibody. For comparison to input material, 25 mg
cdc strains arrested at different points in the cell cycleof lysate was loaded (lanes 1 and 8). Exposure of the cdc28-4 Cln2HA
panel (lanes 5–8) was 60 times longer than the wild-type panel to (Salama et al., 1994). To confirm this, we determined
account for the greatly reduced synthesis of Cln2HA in the cdc28-4 Cln2 half-life in cdc53-1 cells that were prearrested in
culture.
S phase by hydroxyurea prior to shifting to the restrictive(C) Dephosphorylation of Cln2 in vitro abrogates Cdc53 binding.
temperature. As for asynchronous cultures, Cln2 wasLysates from a wild-type strain (K699) expressing <pGAL1-CLN2HA>
(pSL46) as indicated were immunoprecipitated with 12CA5 antibody strongly stabilized in cdc53-1 cells compared with wild-
and then treated with alkaline phosphatase (P9ase) in the presence type cells (Figure 4B). Cln2 was also stabilized in
or absence of phosphatase inhibitors (inh) as indicated. After wash- cdc53-1 cells prearrested in mitosis with nocodazole
ing, immunoprecipitates were incubated with fresh donor lysate
(data not shown). These observations demonstrate thatcontaining either Cdc53 or Cdc53MYC as indicated. Immunoprecipi-
the Cdc53-dependent degradation pathway functionstates were rewashed and immunoblotted with 12CA5 antibody, anti-
Cdc28 antibody, and 9E10 antibody. throughout the cell cycle.
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Cln2 Ubiquitination In Vivo Depends on Cln2
Phosphorylation and Cdc53 Function
Since both Cdc53 and Cdc34 are implicated in a ubiqui-
tin-dependent proteolytic pathway, we sought to estab-
lish whether Cln2 was ubiquitinated in vivo and, if so,
whether this depended on Cln2 phosphorylation. Al-
though Cln2 ubiquitination has been demonstrated in
vitro in yeast extracts (Deshaies et al., 1995), Cln–
ubiquitin conjugates have not previously been detected
invivo. To enhanceour ability todetect such conjugates,
we utilized cells expressing a polyhistidine- and MYC-
tagged K48R, G76A mutant ubiquitin (UbiHIS-MYC-RA). The
K48R mutation prevents the formation of multiubiquitin
chains required for recognition by the proteolytic ma-
chinery (Chau et al., 1989), while the G76A mutation
inhibits the action of ubiquitin hydrolases that remove
ubiquitin from protein–ubiquitin conjugates (Hodgins et
al., 1992). Expression of the UbiHIS-MYC-RA results in accu-
mulation of monoubiquitinated target proteins, which
can be isolated by retention on a Ni21–NTA agarose
Figure 5. Cln2 Ubiquitination In Vivo is Dependent on Phosphoryla-matrix. As detected with a polyclonal anti-Cln2antibody,
tion and Cdc53 and Cdc34 Functionlower mobility forms of Cln2 were retained on the Ni21–
(A) In vivo ubiquitination of Cln2 and Cln24T3S. Wild-type strainsNTA matrix, indicating the presence of Cln2–UbiHIS-MYC-RA
(15Daub) with the following combinations of plasmids were used:conjugates in the cell lysate (Figure 5A, lane 4). The
<pGAL1-CLN2HA> (pSL46) plus <pCUP1-UBIRA> (pUB204) (lanes 1mobility pattern of Cln2 isoforms retained on the matrix
and 2); <pGAL1-CLN2HA> (pSL46) plus <pCUP1-UBIHIS-MYC-RA>
was consistent with multiple phosphorylated species of (pUB223) (lanes 3, 4, and 9); <pGAL1-CLN24T3S-HA> (pSL122) plus
Cln2, each in a monoubiquitinated state. As a control, <pCUP1-UBIRA> (pUB204) (lanes 5 and 6); <pGAL1-CLN24T3S-HA>
Cln2 was not retained when the mutant ubiquitinwas not (pSL122) plus <pCUP1-UBIHIS-MYC-RA> (pUB223) (lanes 7, 8, and 10).
Extracts from cultures expressing the pCUP1 andpGAL1 constructstagged with polyhistidine. Quantitation indicated that
were incubated with Ni21–NTA beads, and bound protein was elutedapproximately 5% of the total Cln2 in the lysate was
with EDTA. Extracts (ex; lanes 1, 3, 5, and 7; 40 mg each) and boundconjugated to UbiHIS-MYC-RA.
proteins isolated from 24 mg of lysate (Ni; lanes 2, 4, 6, and 8–10)The dependence of Cln2 ubiquitination on phosphory-
were analyzed by immunoblotting with affinity-purified anti-Cln2 an-
lation was established by analysis of cells expressing tibodies (lanes 1–8) or monoclonal anti-MYC antibody (9E10; lanes
Cln24T3S. In comparison with wild-type Cln2, ubiquitina- 9 and 10). The presence or absence of a polyhistidine tag on the
tion of Cln24T3S in vivo was diminished at least 10-fold ubiquitin derivative (HIS tag) is indicated.
(B) Cln2 ubiquitination requires both Cdc53 and Cdc34 function. A(Figure 5A, lane 8). Equivalent retention of total ubiqui-
wild-type strain (K699), a cdc53-1 strain (MTY740), and a cdc34-2tin–protein conjugates on the Ni21–NTA resin from both
strain (MTY670) with the following combinations of plasmids wereCln2 and Cln24T3S lysates was confirmed by detection of
used: <pADH1-CLN2HA> (pCB1317) plus <pCUP1-UBIHIS-MYC-RA>the MYC tag on the mutant ubiquitin (Figure 5A, lanes
(pUB223) (lanes 1, 3, 4, 6, 7, and 9–12); <pADH1-CLN2HA> (pCB1317)
9 and 10). These observations demonstrate that phos- plus <pCUP1-UBIRA> (pUB204) (lanes 2, 5, and 8). Extracts (normal-
phorylation of Cln2 is required for efficient targeting of ized for total protein) from cultures grown at 378C and expressing
Cln2 to the ubiquitin proteolytic pathway. the pCUP1 and pADH1 constructs were treated as in (A). Extracts
(adjusted for equal amounts of Cln2; lane 1, 40 mg; lanes 4 and 7,We next determined whether Cdc53 function was re-
3 mg) and bound proteins (lanes 2, 3, 5, 6, 8, and 9–12) were analyzedquired for Cln2 ubiquitination. Cln2HA and UbiHIS-MYC-RA
by immunoblotting with 12CA5 antibody (lanes 1–9) or9E10 antibodywere expressed in a cdc53-1 mutant strain, and accu-
(lanes 10–12). Exposure times for lanes 5, 6, 8, and 9 were reducedmulation of Cln2–ubiquitin conjugates at the restrictive
approximately 10-fold to compensate for the higher concentration
temperature was evaluated (Figure 5B). Whereas Cln2 of Cln2 present in the cdc53 and cdc34 extracts. Lanes 2, 5, and 8
was among the ubiquitin–protein conjugates retained show that binding of nonubiquitinated Cln2 to the Ni–NTA column is
from wild-type cells at 378C (Figure 5B, lane 3), no Cln2 not specific, since it is independent of the HIS tag (see Experimental
Procedures).conjugates wereobserved in lysates from either cdc34-2
or cdc53-1 arrested cells (Figure 5B, lanes 6 and 9). This
was despite the fact that Cln2 accumulated to a much investigated the nature of the two electrophoretic forms
higher level in the mutants relative to wild-type cells of Cdc53. Since neither phosphorylation nor proteolytic
(see Figure 5B, legend). Although nonubiquitinated Cln2 processing could account for the two isoforms (data not
in extracts made from cells grown at 378C was retained shown), we determined whether Cdc53 was ubiquiti-
on the Ni21–NTA resin, this binding was nonspecific, nated. Various tagged versions of Cdc53 were immuno-
since it did not depend on the polyhistidine tag (Figure precipitated from cell lysates with 9E10 antibody and
5B, lanes 2, 5, and 8). Thus, Cdc53, along with Cdc34, immunoblotted with a polyclonal anti-ubiquitin anti-
is required for ubiquitination of Cln2 in vivo. body. A ubiquitinated species corresponding in size to
the lower mobility form of Cdc53 was specifically de-
Cdc53 Is Ubiquitinated and Interacts with Cdc34 tected in Cdc53MYC immunoprecipitates (Figure 6A). The
The physical interaction between Cdc53 and Clns, along extent of the mobility shift caused by ubiquitination of
with the requirement for both Cdc53 and Cdc34 to ubi- Cdc53 was consistent with modification by a single ubi-
quitinate Cln2, suggests that Cdc53 may be an E3 ubi- quitin moiety (Chau et al., 1989). The presence of addi-
tional MYC epitopes on Cdc53 shifted the mobility of thequitin–protein ligase. To characterize Cdc53 further, we
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Cdc34–Cdc53 interaction in vitro with recombinant
Cdc53MYC expressed in insect cells and recombinant
Cdc34 purified from bacteria. Bacterial Cdc34 added to
insect cell lysates was efficiently coimmunoprecipitated
from the lysates with Cdc53MYC (Figure 6C). By compari-
son with known amounts of bacterial Cdc34, we esti-
mate that approximately 4% of the input Cdc34 formeda
complex with Cdc53. Although the involvement of insect
cell proteins cannot be rigorously excluded, relatively
few endogenous proteins would be present in sufficient
abundance to mediate the extent of the Cdc34–Cdc53
interaction we observed. Thus, we conclude from these
experiments that Cdc34 and Cdc53 directly interact to
form a ubiquitin–protein ligase complex.
Discussion
Cdc53 Targets Phosphorylated Clns for
Degradation by the Ubiquitin Pathway
We have found that Cdc53 forms a complex with each
of the G1 cyclins Cln1, Cln2, and Cln3. Several lines of
evidence suggest that the Cln–Cdc53 interaction medi-
ates Cln degradation: Cdc53 interacts specifically with
Clns and not with other cyclins; stabilized versions of
Figure 6. Cdc53 Is Ubiquitinated and Interacts with Cdc34 Cln2 and Cln3 do not interact with Cdc53; CLN2 and
(A) Cdc53 is conjugated to ubiquitin in vivo. Lysates from strains CLN3 overexpression inhibits proliferation of cdc53-1
containing a <CDC53C-NotI> plasmid (MTY721; lanes 1 and 4), a
strains; and Cln2 is stabilized incells defective for Cdc53<CDC53C-MYC3> plasmid (MTY727; lanes 2 and 5) or a <CDC53C-MYC6>
function. It has recently been shown that phosphoryla-plasmid (MTY729; lanes 3 and 6) were immunoprecipitated with
tion of the Cln2 carboxyl terminus is the critical determi-9E10 antibody and immunoblotted with either 9E10 antibody (lanes
1–3) or anti-ubiquitin antibody (lanes 4–6). The number of copies of nant of Cln2 instability (Lanker et al., 1996). Consistent
the MYC epitope on Cdc53 is indicated above each lane. with this view, we have established that the Cln2–Cdc53
(B) Cdc53 interacts with Cdc34 in yeast lysates. Lysates from cells complex depends on Cln2 phosphorylation. Thus, only
carrying either a <CDC53C-NotI> plasmid (MTY721; lane 2) or a
hyperphosphorylated forms of Cln2 interact with Cdc53,<CDC53C-MYC6> plasmid (MTY729; lanes 1 and 3) were immunopre-
the Cln24T3S multiple phosphorylation site mutant doescipitated with either no antibody (lane 1) or with 9E10 antibody (lanes
not interact with Cdc53, and in vitro dephosphorylated2 and 3) and probed with 9E10 antibody or anti-Cdc34 antibody.
(C) Recombinant Cdc53 and Cdc34 interact in baculovirus-infected Cln2 is unable to interact with Cdc53. Finally, we have
insect cell lysates. Equal amounts of lysate from insect cells that demonstrated phosphorylation-dependent ubiquitina-
were infected with either CDC53N-NdeI virus (derived from pMT864; tion of Cln2 in vivo, consistent with previous observa-
lanes 2–5) or CDC53N-MYC3 virus (derived from pMT863; lanes 6–9)
tions using an in vitro extract system (Deshaies et al.,were mixed with increasing amounts of recombinant Cdc34 purified
1995). The formation of Cln2–ubiquitin conjugatesin vivofrom bacteria (4 ng, lanes 2 and 6; 20 ng, lanes 3 and 7; 100 ng,
depends on Cdc53 (and Cdc34) function. A simplelanes 4 and 8; 500 ng, lanes 5 and 9), immunoprecipitated with 9E10
antibody, and immunoblotted with 9E10 antibody and anti-Cdc34 model incorporates all of the above observations:
antibody. We loaded 20 ng of purified Cdc34 as a standard (lane 1). Cdc28-dependent phosphorylation of specific residues
in the Cln carboxyl terminus serves as a conditional
determinant for recognition by Cdc53. Once complexedubiquitinated species, demonstrating that itwas derived
with Cdc53, and probably with Cdc34, the phosphory-from Cdc53 and not from a protein that coimmunopreci-
lated Cln is ubiquitinated and subsequently degradedpitated with Cdc53. Since the Cdc53–ubiquitin conju-
by the ubiquitin proteolytic pathway. This degradativegate was unaffected by harsh reducing conditions in
mechanism serves to render the Cln–Cdc28 kinase com-protein samplebuffer, it isunlikely the ubiquitin is thioes-
plexes highly unstable and therefore responsive to
terified, and it probably does not represent a catalytic
changes in rates of Cln synthesis, as dictated by the
intermediate. However, some members of the HECT
environmental cues that modulate Start.
class of E3 enzymes also form ubiquitin conjugates that
are resistant to reducing conditions (Huibregtse et al.,
1995). Is Cdc53 an E3 Ubiquitin–Protein Ligase?
Selective protein degradation by the ubiquitin pathwayA role for Cdc53 as an E3 ubiquitin–protein ligase was
directly supported by detection of a physical interaction often requires substrate recognition by an E3 ubiquitin–
protein ligase (reviewed by Hochstrasser, 1995). E3 en-between Cdc53 and Cdc34. Initially, we detected coelu-
tion of Cdc34 with Cdc53 from the 12CA5 immunoaffinity zymes can directly participate in the catalytic cascade
of ubiquitin transferase reactions (Scheffner et al., 1995)columns described in Figure 1 (data not shown). We
also detected a specific interaction between Cdc34 and and often reside in multiprotein complexes. For exam-
ple, the E3 for the N-end rule pathway forms a complexCdc53MYC in coimmunoprecipitation experiments from
yeast lysates (Figure 6B). Finally, we reproduced the with its cognate E2 and with other proteins (Madura
Cell
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et al., 1993). Cdc53 fulfills important criteria for an E3 a stable complex with its cognate E2 enzyme Cdc34.
More strikingly, activity of the APC is regulated by Cdc2-ubiquitin–protein ligase as it interacts with both the Cln
substrate and the E2 enzyme Cdc34. In addition to these dependent phosphorylation (Sudakin et al., 1995),
whereas the Cdc53-dependent degradation of Clns isessential protein–protein interactions, Cdc53 is stably
conjugated to ubiquitin, a characteristic shared by some constitutive throughout the cell cycle and is regulated
at the substrate level by phosphorylation.HECT domain E3 ubiquitin–protein ligases (Huibregtse
et al., 1995). It is noteworthy that Cdc53 homologs have G1 cyclin activity is rate limiting for cell division in
yeast, flies, and mammals (reviewed by Sherr, 1994)recently been identified in a number of species from
yeasts to humans (Mathias et al., submitted; Kipreos et and often contributes to tumor progression in human
cancers (reviewed by Hunter and Pines, 1994). Recently,al., 1996), and thus Cdc53 may define a novel class of
E3 ubiquitin–protein ligases. Cdc53 homologs have been identified in a number of
species, including humans (Mathias et al., submitted;We have not yet been able to detect ubiquitin–protein
ligase activity toward Cln substrates with recombinant Kipreos et al., 1996). The potential importance of these
proteins in regulation of cell division in other organismsCdc34 and Cdc53 produced in insect cells. This could
reflect the fact that the Cdc53 complex in yeast may is underscored by the finding that the Cdc53 homolog
encoded by the cul-1 (lin-19) gene in Caenorhabditiscontain other proteins essential for substrate recogni-
tion. For instance, Cdc4 forms a complex with Cdc53 elegans acts to restrain inappropriate cell proliferation
during development (Kipreos et al., 1996). Although the(Mathias et al., submitted; our unpublished data) and
could conceivably facilitate Cdc53–substrate interac- involvement of Cdc53 homologs in G1 cyclin degreda-
tion in metazoans has yet to be established, it is tempt-tions through its WD-40 repeat motifs (Yochem and By-
ers, 1987). Skp1, which is necessary for Cln2 instability ing to speculate that these proteins may act as tumor
suppressors.and binds directly to Cdc4 (Bai et al., 1996), is another
possible component of the Cdc53 complex. Finally,
Grr1, which is required for instability of Cln1 and Cln2 Experimental Procedures
(Barral et al., 1995), may also participate in the Cdc53–
Plasmids and Yeast StrainsCln interaction. Intriguingly, both Cdc4 and Grr1 contain
Plasmids are listed in Table 1. A 3.6 kb EcoRI fragment (Mathias eta novel motif first identified in cyclin F, called the F-box;
al., submitted) containing the CDC53 gene and 600 bp of upstream
this motif is essential for the interaction of Cdc4 with promoter sequence was cloned into pRS314 and pRS424 (Sikorski
Skp1 (Bai et al., 1996). Definition of the role these pro- and Hieter, 1989). To epitope tag Cdc53 at the amino terminus,
teins play in Cln recognition and ubiquitination awaits artificial BamHI and NdeI sites were placed at the 59 end of the
CDC53 coding region by site-directed mutagenesis, and a tandemfurther biochemical characterization of the Cdc53
triple MYC epitope (Schneider et al., 1995) was inserted into thecomplex.
NdeI site. To epitope tag Cdc53 at the carboxyl terminus, either oneThe Clns cannot be the only substrates of the Cdc34–
or two copies of the triple MYC epitope were inserted into a NotI
Cdc53 pathway, since stable Cln mutant strains are via- site placed immediately prior to the termination codon. The NotI
ble, whereas cells lacking Cdc34 or Cdc53 function are site introduces an extra Ser-Gly-Ala at the carboxyl terminus of
inviable. The hyperactivation of Start caused by Cln sta- Cdc53. All epitope-tagged versions of CDC53 were able to comple-
ment fully a strain deleted for the CDC53 reading frame. An HAbilization is probably obscured in cdc34 and cdc53
epitope–tagged truncation allele of CLN2 analogous to CLN2-1strains by stabilization of p40SIC1,which causes cell cycle
(Hadwiger et al., 1989b) and CLN2T (Salama et al., 1994) was madearrest prior to DNA replication (Schwob et al., 1994).
by placing a NotI site followed by a termination codon at nucleotide
Like Cln degradation, p40SIC1 degradation depends on position 1132 of CLN2 and inserting a triple HA epitope (Tyers et
phosphorylation by the Cln–Cdc28 kinases (Schwob et al., 1992). We refer to this allele as CLN2-1HA. All mutagenized regions
al., 1994; Schneider et al., 1996; Tyers, 1996), suggesting were completely sequenced to ensure random mutations did not
arise during mutagenesis.that phosphorylation may trigger degradation of all sub-
Yeast strains are listed in Table 2. MTY740 was created by back-strates targeted by the Cdc34–Cdc53 pathway. Other
crossing MGG28 to K699 (W303 background) four times. All otherproteins that are either degraded or ubiquitinated in a
W303 strains were backcrossed to K699 at least six times. Yeast
Cdc34-dependent manner include Gcn4, Far1, and Cbf2 were transformed and cultured by standard methods (Kaiser et al.,
(McKinney et al., 1993; Kornitzer et al., 1994; Yoon and 1994). All carbon sources were used at 2% w/v. For induction of
Carbon, 1995). It will be of interest to determine whether pGAL1 expression constructs, strains were grown to a density of
0.5 3 107 to 1.0 3 107 cells per milliliter in raffinose and induceddegradation of these proteins requires Cdc53 function.
with galactose for 2 hr.
Immunoaffinity Column ChromatographyConserved Proteolytic Mechanisms of Cell
A preparative scale anti-HA antibody column was made by cross-Cycle Regulation
linking IgG from 1–2 ml of 12CA5 ascites fluid (approximately 10The APC is a conserved ubiquitin–protein ligase that
mg/ml total IgG) to a 1 ml volume of protein A beads with dimethyl-
catalyzes ubiquitination of mitotic cyclins and probably suberimidate (Harlow and Lane, 1988). Lysates were made from
other proteins (reviewed by Murray, 1995). We have pro- <pADH1-CLN2HA> cdc34-2 cells that had been arrested at 378C for
4–6 hr at a density of 2 3 107 cells per milliliter in batches of 25 l.vided evidence that Cdc53 fulfills an analogous function
Cell pellets were resuspended in an equal volume of buffer 3 plusin G1 cyclin degradation at Start. Like the APC, the
protease inhibitors (Tyers et al., 1993) and lysed by grinding withCdc34–Cdc53 complex probably has multiple targets,
glass beads in a bead beater that was cooled by an ice water bath.including the Clns and p40SIC1. However, unlike the APC,
The lysate (approximately 200 ml, with 50 mg of protein per milliliter)
which is chromatographically separable from the E2 ac- was clarified by centrifugation at 100,000 3 g for 1 hr and then
tivity required for cyclin ubiquitination (King et al., 1995; passed over a 12CA5 column by gravity flow at 48C. Columns were
washed with 10–20 ml of buffer 3, and bound proteins were elutedSudakin et al., 1995), we have found that Cdc53 forms
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Table 1. Plasmid List
Plasmid Relevant Characteristics Source
pMT41 pGAL1-CLN3HA URA3 2mm G. Tokiwa
pMT42 pGAL1-CLN3-1HA URA3 2mm G. Tokiwa
pMT112 CLN2-1HA-LEU2 in pUC119 This study
pMT215 pGAL1-CLN3-1 URA3 2mm G. Tokiwa
pMT290 pGAL1-CLN2HA-LEU2 in pUC119 This study
pMT485 pGAL1-CLN1HA URA3 CEN G. Tokiwa
pMT634 pGAL1-CLN2HA LEU2 URA3 CEN This study
pMT704 CDC53 TRP1 CEN This study
pMT706 CDC53 TRP1 2mm This study
pMT721 CDC53N-NdeI TRP1 2mm This study
pMT722 CDC53N-MYC3 TRP1 2mm This study
pMT816 CDC53C-NotI TRP1 CEN This study
pMT841 CDC53C-MYC3 TRP1 CEN This study
pMT843 CDC53C-MYC6 TRP1 CEN This study
pMT863 CDC53N-MYC3 in pBlueBacIII This study
pMT864 CDC53N-NdeI in pBlueBacIII This study
pSL46 pGAL1-CLN2HA URA3 CEN This study
pSL122 pGAL1-CLN24T3S-HA URA3 CEN This study
pUB204 pCUP1-UBIRA TRP1 CEN S. Sadis, D. Finley
pUB223 pCUP1-UBIHIS-MYC-RA TRP1 CEN S. Sadis, D. Finley
pCB1310 Sp-pADH1-CLN2HA LEU2 CEN K. Arndt
pCB1317 Sc-pADH1-CLN2HA LEU2 CEN K. Arndt
pWS935 pGAL1-CLB2HA URA3 CEN W. Seufert
pWS12933 pGAL1-CLB5HA URA3 CEN W. Seufert
with 100 mM triethylamine. Control untagged column eluates were gel with 50% acetonitrile and separated by HPLC on a Vydac C18
column (1.0 3 250 mm, 10 mm, 300 A˚). Each peptide was sequencedgenerated from a starting culture that lacked the <pADH1-CLN2HA>
plasmid. Analytical scale immunoaffinity columns were performed by automated protein sequencers (Applied Biosystems models 470,
473, and 477). For p94, 11 peptides corresponded to the deducedin a similar manner, with the exceptions that cell lysates were pre-
pared by grinding frozen cell pellets in liquid nitrogen (Schultz et Cdc53 sequence, two peptides (LTDSLVQRAG; DLMLYVSK) corre-
sponded to yeast EF-2 sequence, and one peptide (YQPAALIA-al., 1991) and affinity column buffer was used for cell lysis and
column elution (Sopta et al., 1985). GEERK) did not match any known sequence.
Protein and RNA AnalysisProtein Sequencing
Proteins in preparative scale column fractions were separated by Immunoprecipitations and immunoblots were processed for ECL
(Amersham) detection as described previously (Tyers et al., 1993),SDS–PAGE and detected by staining with high purity Coomassie
brilliant blue (Sigma, B-5133). Protein bands were excised from the except that cell lysates were made by grinding in liquid nitrogen
(Schultz et al., 1991). RNA was isolated and analyzed as describedgel, washed twice with 50% methanol, and digested with 500 ng of
Achromobacter protease I in 0.1% Tween 20, 0.1 M Tris–HCl (pH previously (Tyers et al., 1993). Affinity-purified antibodies against
Cdc53 and Cdc34 (Mathias et al., submitted), crude anti-Cdc289.0) for 20 hr at 308C. Peptide fragments were extracted from the
Table 2. Strain List
Strain Name Relevant Genotypea Background Source
MTY251 cln2::CLN2-1HA-LEU2 W303 This study
MTY386 cln2::pGAL1-CLN2HA-LEU2 W303 This study
MTY670 cdc34-2 W303 This study
MTY721b cdc53::URA3, pMT816 plasmid S288C This study
MTY727b cdc53::URA3, pMT841 plasmid S288C This study
MTY729b cdc53::URA3, pMT843 plasmid S288C This study
MTY738 cln2::CLN2HA W303 This study
MTY740 cdc53-1 W303 This study
MTY777 cln2::pGAL1-CLN2HA-LEU2 cdc34-2 W303 This study
MTY784 cln2::pGAL1-CLN2HA-LEU2 cdc53-1 W303 This study
K699 ade2-1 can1-100 his3-1,15 leu2-3,112 trp1-1 ura3 W303 K. Nasmyth
K1989 cdc28-4 W303 K. Nasmyth
BF305-15d ade1 arg5,6 his3 leu2 met14 trp1 ura3 BF305-15d B. Futcher
RN200-6d cdc34-2 BF305-15d B. Futcher
GT101-14c cdc34-2 cln2::CLN2HA BF305-15d B. Futcher
MGG28 his3D leu2-3,112 trp1Dura3-52 cdc53-1 S288C M. Goebl
KC108 MATa/a CAN1/can1 CYH2/cyh2r leu2-D1/leu2-D1 S288C M. Goebl
trp1-D63/trp1-D63 ura3-52/ura3-52
CDC53/cdc53::mTn3(URA3)
15Daub bar1Dade1 his2 leu2-3,112 trp1 ura3 BF264-15D S. Reed
a Unless indicated, strains are MATa.
b Derived from KC108.
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antibody (provided by M. Mendenhall), and anti-ubiquitin antibody ubiquitin proteolysis machinery through a novel motif, the F-box.
Cell 86, 263–274.(Sigma, U5379) were all used at a dilution of 1:1000. 12CA5 and
9E10 monoclonal antibodies were produced as ascites fluid (Kolod- Baroni, M.D., Monti, P., and Alberghina, L. (1994). Repression of
ziej and Young, 1991) and used at a dilution of 1:10,000. For Cdc53 growth-regulated G1 cyclin expression by cyclic AMP in budding
rebinding assays, Cln2 immunoprecipitates were dephosphorylated yeast. Nature 371, 339–342.
using 20 U of calf intestinal alkaline phosphatase essentially as
Barral, Y., Jentsch, S., and Mann, C. (1995). G1 cyclin turnover and
described previously (Lanker et al., 1996), washed with buffer 3,
nutrient uptake are controlled by a common pathway in yeast. Genes
incubated with 2 mg of donor lysate for 1–2 hr at 48C, rewashed
Dev. 9, 399–409.
with buffer 3, and immunoblotted.
Chau, V., Tobias, J.W.,Bachmair, A., Marriott, D., Ecker, D.J., Gonda,
D.K., and Varshavsky, A. (1989). A multiubiquitin chain is confinedDetection of Cln2–Ubiquitin Conjugates
to specific lysine in a targeted short-lived protein. Science 243,Strains were grown in selective medium containing sucrose to early
1576–1583.log phase, and the CUP1 promoter was induced by the addition of
Cross, F.R. (1988). DAF1, a mutant gene affecting size control, pher-CuSO4 to 250 mM. Temperature-sensitive strains were shifted to
omone arrest, and cell cycle kinetics of Saccharomyces cerevisiae.378C at the time of CuSO4 addition. After 5 hr, galactose was added
Mol. Cell. Biol. 8, 4675–4684.to 2% and the cells were grown for 1 hr. Cell pellets were solubilized
in buffer G (6 M guanidinium hydrochloride, 0.1 M NaH2PO4, 20 mM Cross, F.R. (1995). Starting the cell cycle: what’s the point? Curr.
Tris–HCl [pH 8.0]) by glass bead lysis. After centrifugation (15 min Opin. Cell Biol. 7, 790–797.
at 14,000 3 g), clarified extracts containing 24 mg of total protein Deshaies, R.J., Chau, V., and Kirschner, M. (1995). Ubiquitination of
were incubated with Ni21–NTA agarose resin (Qiagen) for 1 hr at the G1 cyclin Cln2p by a Cdc34p-dependent pathway. EMBO J. 14,
room temperature. The beads were washed three times with buffer 303–312.
G and three times with buffer C (50 mM Tris–HCl [pH 8.0], 500
Dirick, L., Bohm, T., and Nasmyth, K. (1995). Roles and regulationmM NaCl). For experiments with strains grown at 378C, nonspecific
of Cln-Cdc28 kinases at the start of the cell cycle of Saccharomycesbackground was not reduced either by inclusion of 40 mM imidazole
cerevisiae. EMBO J. 14, 4803–4813.during binding or by inclusion of 100 mM imidazole in buffer C.
Evans, T., Rosenthal, E.T., Youngblom, J., Distel, D., and Hunt, T.Bound proteins were eluted by addition of buffer E (100 mM Tris–HCl
(1983). Cyclin: a protein specified by maternal mRNA in sea urchin[pH 6.8], 1% SDS, 100 mM DTT, 100 mM EDTA) and immunoblotted.
eggs that is destroyed at each cleavage division. Cell 33, 389–396.
Baculovirus Expression of Cdc53 in Insect Cells Fitch, I., Dahmann, C., Surana, U., Amon, A., Nasmyth, K., Goetsch,
pBlueBacIII transfer vectors were mixed with linear wild-type L., Byers, B., and Futcher, B. (1992). Characterization of four B-type
AcMNPV viral DNA and transfected into Sf9 insect cells (Invitrogen). cyclin genes of the budding yeast Saccharomyces cerevisiae. Mol.
Plaques expressing Cdc53 and Cdc53N-MYC were purified and ampli- Biol. Cell 3, 805–818.
fied in Sf9 cells. Lysates were prepared by infecting 100 mm dishes Glotzer, M., Murray, A.W., and Kirschner, M.W. (1991). Cyclin is
of confluent High Five cells (Invitrogen) with recombinant virus at degraded by the ubiquitin pathway. Nature 349, 132–138.
moi 5 5. After 46 hr, cells were pelleted, washed once in phosphate-
Goebl, M.G., Yochem, J., Jentsch, S., McGrath, J.P., Varshavsky,buffered saline plus 1 mM EDTA, and lysed in 400 ml of buffer 3 by
A., and Byers, B. (1988). The yeast cell cycle gene CDC34 encodessix passes through a 25-gauge syringe. After clarification (10 min
a ubiquitin-conjugating enzyme. Science 241, 1331–1335.at 10,000 3 g), lysates typically contained 10 mg/ml of protein,
Hadwiger, J.A., Wittenberg, C., Mendenhall, M.D., and Reed, S.I.approximately 0.3% of which was Cdc53N-MYC. Purified recombinant
(1989a). The Saccharomyces cerevisiae CKS1 gene, a homolog ofCdc34 produced in bacteria (provided by N. Steussy) was incubated
the Schizosaccharomyces pombe suc11 gene, encodes a subunitwith 20 ml of insect cell lysate on ice for 3 hr prior to immunoprecipi-
of the Cdc28 protein kinase complex. Mol. Cell. Biol. 9, 2034–2041.tation.
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